Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients

NCT01983995 | Completed

• 2 other identifiers: HUM00078882UMCC 2013.098
• Study Type: observational
• Target: 49
• Locations: 1 country
• Sites: 1

Brief Summary

Aromatase inhibitors are commonly prescribed for treatment of postmenopausal women with breast cancer. These medications can cause side effects in some women, and occasionally they can be quite bothersome. We are doing a study to better understand the side effects of aromatase inhibitors so that we can hopefully treat them better or possibly prevent them. In particular, we are interested in pain and difficulty sleeping. This study is designed to assess the effect of aromatase inhibitors on pain, sleep quality, and fatigue and the interplay of these side effects and their subsequent impact on daily activity. Each participant will fill out a series of questionnaires about pain, sleep quality, and fatigue and will also complete a sleep diary and wear an actigraphy watch for 10 days before starting an aromatase inhibitor and after taking it for 3 months. We hope to learn more about these symptoms so we can better manage medication toxicity in the future.

Conditions

Breast Cancer

Keywords

Breast Cancer; Aromatase Inhibitors; Actigraphy; Pain; Fatigue; Sleep quality

Outcome Measures

Primary Outcomes (1)

• Feasibility of conducting an actigraphy study with breast cancer patients

  Feasibility will be measured by the proportion of breast cancer patients who are starting aromatase inhibitor therapy who complete baseline and 3 month assessment questionnaires and also enter actigraphy data correctly at least 85% of the time.

  3 months

Secondary Outcomes (2)

• Association between patient-reported sleep quality, fatigue, and pain and objective actigraphy measurements.

  3 months

• Change in pain, fatigue, sleep disturbance, and daytime activity with 3 months of aromatase inhibitor therapy

  3 Months

Study Arms (1)

Actigraphy

Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.

Eligibility Criteria

• Age: 50 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

University of Michigan Cancer Center

You may qualify if:

• Female, aged 50 years or older, postmenopausal.
• Patients with histologically proven stage 0-III invasive carcinoma of the breast that is estrogen receptor and/or progesterone receptor positive by immunohistochemical staining, who are planning to start treatment with a standard dose of aromatase inhibitor (AI) therapy.
• Subjects must have undergone surgical resection of their primary tumor, as indicated. The most recent surgery must have been performed at least 4 weeks before the baseline evaluation and no additional surgeries (including reconstructive procedures) should be planned during study participation.
• Cytoxic chemotherapy, if applicable, must have been completed at least 4 weeks before the baseline evaluation.
• Radiation therapy, if applicable, must have been completed at least 2 weeks before baseline evaluation.
• Eastern Cooperative Oncology Group performance status 0-2.
• Ability to operate the accelerometer

You may not qualify if:

• Diagnosis of sleep apnea or restless leg syndrome.
• Use of a wheelchair for ambulation most of the time.
• Second or third shift workers or other non-traditional sleep schedules.
• History of medical arthritic disease that could confound or interfere with evaluation of pain or activity level, including but not limited to inflammatory arthritis (rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica), Parkinson's disease, and cancer involving the bone.
• Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

Sponsors & Collaborators

• University of Michigan: lead
• Damon Runyon Cancer Research Foundation: collaborator

Study Sites (1)

University of Michigan Health System

Ann Arbor, Michigan, 48109, United States

Location

MeSH Terms

Conditions

Breast Neoplasms; Pain; Fatigue; Sleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Study Officials

• Norah L Henry, MD, PhD

  University of Michigan

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Internal Medicine, Medical School

Study Record Dates

• First Submitted: November 7, 2013
• First Posted: November 14, 2013
• Study Start: November 1, 2013
• Primary Completion: September 1, 2016
• Study Completion: September 1, 2016
• Last Updated: October 25, 2016

Record last verified: 2016-10

Locations

US (1)